COLL Collegium Pharmaceutical Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: COLL

Price (delayed)

$36.08

Market cap

$1.18B

P/E Ratio

12.84

Dividend/share

N/A

EPS

$2.81

Enterprise value

$1.58B

Collegium Pharmaceutical Inc. is a specialty pharmaceutical company committed to being the leader in responsible pain management. Collegium's headquarters are located in Stoughton, Massachusetts.

Highlights
Collegium Pharmaceutical's EPS has soared by 97% from the previous quarter
The net income has soared by 94% from the previous quarter
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.collegiumpharma.com
Peers: UTHR LPCN SUPN

Key stats

What are the main financial stats of COLL
Market
Shares outstanding
32.72M
Market cap
$1.18B
Enterprise value
$1.58B
Valuations
Price to earnings (P/E)
12.84
Price to book (P/B)
5.19
Price to sales (P/S)
2.06
EV/EBIT
7.56
EV/EBITDA
4.41
EV/Sales
2.79
Earnings
Revenue
$566.92M
EBIT
$209.16M
EBITDA
$358.62M
Free cash flow
$308.16M
Per share
EPS
$2.81
Free cash flow per share
$9.53
Book value per share
$6.95
Revenue per share
$17.54
TBVPS
$18.35
Balance sheet
Total assets
$1.11B
Total liabilities
$892.08M
Debt
$629.99M
Equity
$222.17M
Working capital
$92.82M
Liquidity
Debt to equity
2.84
Current ratio
1.21
Quick ratio
1.11
Net debt/EBITDA
1.12
Margins
EBITDA margin
63.3%
Gross margin
60%
Net margin
16.5%
Operating margin
33.8%
Efficiency
Return on assets
8%
Return on equity
46.8%
Return on invested capital
36%
Return on capital employed
31.3%
Return on sales
36.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

COLL stock price

How has the Collegium Pharmaceutical stock price performed over time
Intraday
1.86%
1 week
11.5%
1 month
13.35%
1 year
67.27%
YTD
17.22%
QTD
12.05%

Financial performance

How have Collegium Pharmaceutical's revenue and profit performed over time
Revenue
$566.92M
Gross profit
$340.22M
Operating income
$191.81M
Net income
$93.29M
Gross margin
60%
Net margin
16.5%
Collegium Pharmaceutical's operating income has surged by 182% YoY and by 15% QoQ
Collegium Pharmaceutical's operating margin has surged by 162% YoY and by 15% QoQ
The net income has soared by 94% from the previous quarter
COLL's net margin has surged by 94% since the previous quarter

Growth

What is Collegium Pharmaceutical's growth rate over time

Valuation

What is Collegium Pharmaceutical stock price valuation
COLL P/E details
P/E
12.84
P/B
5.19
P/S
2.06
EV/EBIT
7.56
EV/EBITDA
4.41
EV/Sales
2.79
Collegium Pharmaceutical's EPS has soared by 97% from the previous quarter
The price to book (P/B) is 27% higher than the 5-year quarterly average of 4.1 and 10% higher than the last 4 quarters average of 4.7
The equity is up by 24% year-on-year and by 14% since the previous quarter
COLL's price to sales (P/S) is 21% higher than its last 4 quarters average of 1.7 and 3% higher than its 5-year quarterly average of 2.0
The revenue is up by 8% year-on-year

Efficiency

How efficient is Collegium Pharmaceutical business performance
The company's return on assets has surged by 95% QoQ
The ROE has soared by 84% QoQ
The ROIC has grown by 38% from the previous quarter
Collegium Pharmaceutical's ROS has increased by 31% from the previous quarter

Dividends

What is COLL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for COLL.

Financial health

How did Collegium Pharmaceutical financials performed over time
Collegium Pharmaceutical's total assets is 25% more than its total liabilities
Collegium Pharmaceutical's total liabilities has decreased by 14% YoY and by 6% QoQ
Collegium Pharmaceutical's total assets has decreased by 8% YoY and by 2.5% from the previous quarter
COLL's debt is 184% greater than its equity
The debt to equity fell by 37% YoY and by 18% QoQ
The equity is up by 24% year-on-year and by 14% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.